Natasha is a Research Associate in the Behaviour and Health Research Unit at the University of Cambridge. She has an MSc in Research Methods in Psychology and recently obtained a PhD from the University of Liverpool which focussed on developing interventions to reduce alcohol-related harm, specifically by altering the drinking environment (including labelling, warning messages, glass shape). Natasha is specifically interested in how such interventions can be applied and carried out in real life settings. She enjoys blogging, and writes both opinion and research pieces for her own blog (‘Diary of an Alcohol Researcher’ https://tash13579.wordpress.com/) whenever she finds the time.
Natasha Clarke explores a systematic review of Whole of Community interventions to reduce population level harms arising from alcohol and other drug use.[read the full story...]
Natasha Clarke considers a systematic review and meta-analysis of longitudinal studies, which looks at modifiable parenting factors associated with adolescent alcohol misuse.[read the full story...]
Natasha Clarke considers the measurable effects of local alcohol licensing policies on population health in England.[read the full story...]
Natasha Clarke and Matt Field comment on a recent BMJ Head to Head discussion, which asks could campaigns like Dry January do more harm than good?[read the full story...]
Natasha Clarke helps us understand a recent systematic review of prospective cohort studies, which explores the links between parental alcohol drinking and alcohol consumption in their offspring.[read the full story...]
Natasha Clarke summarises a recent Cochrane review of pharmacotherapy for anxiety and comorbid alcohol use disorders, which found only very low quality evidence about the effectiveness of medication (buspirone, paroxetine, sertraline) for treating patients with both conditions.[read the full story...]
Natasha Clarke publishes her debut Mental Elf blog about a new systematic review and meta-analysis investigating the risk of neuropsychiatric adverse events associated with the smoking cessation drug varenicline.[read the full story...]